PubMed Health⌕ Search

PubMed · 12228764

Cyclosporin A and FK506 decrease adenosine kinase activity and adenosine uptake in T-lymphocytes.

Abstract

Adenosine is a potent modulator of immune function, and adenosine kinase (AK), a rate-limiting enzyme for adenosine uptake and metabolism, is a potential mediator of adenosine regulation. We have found that adenosine uptake increased six- to 18-fold during T-lymphocyte activation. This increase correlated with an increase in AK activity but not in AK protein. The immunosuppressive drugs cyclosporin A (CsA) and FK506 inhibited both adenosine uptake and AK activity in a concentration-dependent manner. Among several nucleosides and bases, the inhibition of uptake was selective for adenosine. Immunosuppressive drug treatment also caused a twofold increase in the level of extracellular adenosine but not of inosine, suggesting that the effect is not related to the general toxicity of drugs. Inhibitors of calcineurin did not inhibit adenosine uptake, suggesting that this protein phosphatase does not mediate the effect. These data demonstrate that CsA and FK506 enhance adenosine concentrations in T-lymphocytes by way of a mechanism that involves AK inhibition.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Jozef Spychala, Beverly S Mitchell. 2002. Cyclosporin A and FK506 decrease adenosine kinase activity and adenosine uptake in T-lymphocytes.. https://doi.org/10.1067/mlc.2002.125798

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Modulation of the skeletal muscle Ca2+ release channel/ryanodine receptor by adenosine and its metabolites: a structure-activity approach.

Activation of ryanodine receptor (RyR) from skeletal muscle sarcoplasmic reticulum by adenosine and adenosine's metabolites was studied. The purines tested increased the [3H]-ryanodine binding as follows: xanthine>adenosine>adenine >inosine>/=uric acid>hypoxanthine. The enhanced [3H]-ryanodine binding did not involve change in the RyR-Ca(2+) sensitivity and was due mainly to lower values in the affinity constant (K(d)) that corresponded with an increase in the association rate constant (K(+1)). [3H]-ryanodine maximum binding (B(max)) was much less affected. Adenosine and inosine effects were dependent on the presence beta-glycosidic bond within the ribose ring, since the combination of adenine or hypoxanthine with ribose was not able to emulate the nucleosides' original activation. Competition experiments with AMP-PCP, a non-hydrolyzable analogue of ATP, evidenced a nucleotide's inhibitory influence on the adenosine and xanthine activation of the RyR. As a result of a Quantitative Structure-Activity Relationship (QSAR) study, we found a significant correlation between the modulation by adenosine and its metabolites on RyR activity and the components of their calculated dipole moment vector. Our results show that the ribose moiety and the dipole moment vector could be factors that make possible the modulation of the RyR activity by adenosine and its metabolites.

Adenosine↗

Modification of cardiovascular response of posterior hypothalamic adenosine A(2) receptor stimulation by adenylate cylase, guanylate cyclase and by K(ATP) channel blockade in anesthetized rats.

Cardiovascular inhibitory effects induced by posterior hypothalamic adenosine A(2) receptors and their modulation by nitric oxide were suggested by our previous report. In this experiment, we examined the modulation of cardiovascular effects of adenosine A(2) receptor stimulation by adenylate cyclase, guanylate cyclase and ATP-sensitive K(+) channel in the posterior hypothalamus. Posterior hypothalamic injection of drugs was performed in anesthetized, artificially ventilated male Sprague-Dawley rats. Injection of adenosine A(2) receptor agonist 5'-(N-cyclopropyl)-carboxamidoadenosine (CPCA; 1, 2 and 5 nmol) produced a dose-dependent decrease of blood pressure and heart rate. Pretreatment with adenosine A(2) receptor antagonist 3,7-dimethyl-1-propargylxanthine (10 nmol) blocked the depressor and bradycardiac effects of CPCA (5 nmol). Pretreatments with adenylate cyclase inhibitor MDL-12330 (10 nmol) and guanylate cyclase inhibitor LY-83583 (5 nmol) attenuated the depressor and bradycardiac effects of CPCA (5 nmol). In addition, pretreatment with ATP-sensitive K(+) channel blocker glipizide (20 nmol) attenuated the depressor and bradycardiac responses of CPCA (5 nmol). These results suggest that posterior hypothalamic adenosine A(2) receptors play an inhibitory role in the central cardiovascular regulation and that both adenylate cyclase and guanylate cyclase mediate the depressor and bradycardiac actions of adenosine A(2) receptors. Also, ATP-sensitive K(+) channel mediates the posterior hypothalamic cardiovascular regulations of adenosine A(2) receptors.

Adenosine↗

Unexpected inhibition of S-adenosyl-L-homocysteine hydrolase by a guanosine nucleoside.

A series of shape-modified flexible nucleosides ('fleximers', 1, 2, and 3) was modeled, synthesized and subsequently assayed against S-adenosyl-L-homocysteine hydrolase (SAHase). No inhibitory activity was observed for the adenosine fleximer, which served as a substrate, but moderate inhibitory activity was exhibited by the guanosine fleximers. This is the first known report of a guanosine nucleoside analogue possessing activity against SAHase.

Adenosine↗